Region — International. Neutral scientific reference — not offered for sale here.
Research reference — not for sale
Cagrilintide
Blead outcome
Weight loss — CagriSema (combination)
grades vary by outcome ↓
Peptide
also called — cagrilintide · a long-acting amylin analog · a dual amylin and calcitonin receptor agonist (DACRA) · combined with semaglutide as CagriSema. Developer: Novo Nordisk. INCI: none
metabolicobesity / weightamylin (investigational)
Reference entry — NOT a sellable lane, NOT yet approved. Notable because it's not a GLP-1 at all — a different class (amylin) with a genuinely different mechanism. Investigational; its future rides on the CagriSema combination, filed with the FDA in Dec 2025. No dosing published here.
In brief
Cagrilintide is a long-acting amylin analog — a genuinely different mechanism from the GLP-1 drugs, acting on amylin/calcitonin receptors in the brainstem. Its future is tied to CagriSema (cagrilintide + semaglutide), the first GLP-1 + amylin combination, which produced ~20–23% weight loss in Phase 3 and was filed with the FDA in December 2025 (decision expected late 2026). The data are strong — but it is not yet approved anywhere, and it already faces a successor in Novo's own pipeline (amycretin).
Legal standing, by region
- Everywhere — investigational, not approved. Cagrilintide is not available by prescription or through compounding pharmacies outside clinical trials. CagriSema is under FDA review (filed Dec 2025; decision expected late 2026).
- Gray market: "research" cagrilintide is sold online but is unapproved and unregulated — unknown purity/dose.
- This venture: not a sellable lane — an investigational drug.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
OutcomeEvidence base · effectGrade
Weight loss — CagriSema (combination)
Strong Phase 3 and FDA-filed, but not yet approved; the result disappointed inflated expectations
Phase 3 REDEFINE-1/-2 (~20–23%); NDA filed Dec 2025 · Substantial (tirzepatide-comparable)
BWeight loss — cagrilintide monotherapy
Not being filed standalone; lower nausea than GLP-1
Phase 2 (Lancet 2021, ~10.8%) + REDEFINE arm (~11.8%) · Meaningful; comparable to semaglutide alone
BAmylin / satiety mechanism
Mechanistically distinct from GLP-1
Established amylin biology · Real, complementary pathway
—Safety
Combination GI effects are additive; serious events (pancreatitis, gallbladder) similar to semaglutide; investigational
REDEFINE programme · Class-similar; monotherapy has less nausea
—Disclosure
Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.
Evidence changes
Get notified if this changes
We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Cagrilintide changes - nothing else.
Identity
a long-acting synthetic analog of amylin — a peptide hormone co-secreted with insulin by pancreatic beta cells that signals fullness. Cagrilintide is engineered with a fatty-acid chain for once-weekly dosing, and it acts on amylin receptors (AMY1/2/3R) and the calcitonin receptor in the area postrema — a brainstem region that sits outside the blood-brain barrier. Critically, it is not a GLP-1 agonist — it's a separate satiety pathway.
Mechanism (as proposed)
a dual amylin + calcitonin receptor agonist acting on the area postrema (brainstem, outside the blood-brain barrier) → promotes satiety, slows gastric emptying, and suppresses glucagon. Because this is a different brain target from GLP-1's hypothalamic action, the two combine additively in CagriSema.
Chemical identifiers
Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.
InChIKeyLDERDVMBIYGIOI-IZVMHKDJSA-N
SMILESCC[C@H](C)[C@@H](C(=O)N[C@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](CC(=O)N)C(=O)N[C@H](C(C)C)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](CC(=O)N)C(=O)N[C@H]([C@H](C)O)C(=O)N3CCC[C@@H]3C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O
via PubChem exact-name match (Cagrilintide) · high confidence
Sources — 4 cited
01Lau DCW, Le Roux CW, et al. Cagrilintide, a long-acting amylin analogue: a Phase 2 randomised dose-finding study in obesity. Lancet. 2021.
02Frias JP, et al. (Cagrilintide + semaglutide in type-2 diabetes — Phase 2.) Lancet. 2023.
03Garvey WT, et al. (CagriSema — REDEFINE-1 Phase 3.) N Engl J Med. 2025.
04Novo Nordisk — REDEFINE-1 topline (Dec 2024) and FDA NDA submission (Dec 2025).
Updated 2026-07-13 (fast-moving — re-check the late-2026 FDA decision on CagriSema)
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
VallydiaA neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
Region — International
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.